Encoded Therapeutics Presents New Clinical Data from POLARIS Phase 1/2 Trials of ETX101 Gene Therapy in Dravet Syndrome at the ASGCT 2026 Presidential Symposium

AI Briefing

• – Encoded Therapeutics presents new clinical data from POLARIS Phase 1/2 trials of ETX101 gene therapy in Dravet syndrome at the ASGCT 2026 Presidential Symposium.
• – Updated data from the trials includes additional patients and early results from the top dose level.
• – Company's investigational AAV9-based gene regulation therapy aims to be a one-time, disease-modifying treatment for SCN1A+ Dravet syndrome.